Jim Cramer endorses Uranium Energy Corp amid market shifts
- Jim Cramer praised Uranium Energy Corp. for its acquisition of Rio Tinto's Wyoming assets, which enhances its uranium resources.
- Concerns about Novo Nordisk's proposed acquisition of Catalent Inc. have arisen, with critics warning of potential antitrust issues.
- Cramer's recommendations suggest a cautious approach to investing in Halliburton, indicating a mixed outlook for these companies.
In the United States, Jim Cramer expressed optimism about Uranium Energy Corp. (UEC) during a segment on CNBC's 'Mad Money Lightning Round.' He highlighted the company's recent acquisition of Rio Tinto Plc's Wyoming assets for $175 million, which includes the Sweetwater Plant and significant uranium resources. Cramer also commented on Novo Nordisk, suggesting that it is not as competitive as Eli Lilly, especially amid antitrust concerns regarding Novo's proposed $16.5 billion acquisition of Catalent Inc. Critics fear this merger could lead to higher prices and reduced competition in the diabetes and obesity drug market. Additionally, Cramer advised against investing in Halliburton, despite a Buy rating from BofA Securities, which lowered its price target for the company. The stock market reacted with mixed results, as shares of Novo Nordisk fell slightly, while Uranium Energy saw a modest increase, and Halliburton's shares declined.